Shoreline Biosciences, an immunotherapy company formed in 2020 during the early days of the COVID-19 pandemic, was propelled into the proverbial catbird’s seat this summer with two mega-deals, and now plans to double its employee base from 50 to 100 in the coming six to nine months. Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic […]

The capabilities of the biotech industry are stretching further than previously thought possible. Thanks to research, manufacturing capabilities, and other forms of innovation, cell therapies that were once an aspiration for the distant future are now a reality. The promise of cell therapies lies in the fact that they are essentially living drugs working in […]

The U.S. Food and Drug Administration (FDA) has approved a fast track designation for STRO-002, a folate receptor α–targeting antibody-drug conjugate, for the treatment of advanced, platinum-resistant ovarian cancer. Sutro Biopharma, the company that develops the drug, said the FDA approved the use of STRO-002 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian […]